B2M and melanoma: The data related to the loss of β2M function are also consistent with findings from other solid tumours such as melanoma.75 An investigational molecular analysis of a melanoma patient who developed resistance to immunotherapy also showed loss of MHC class I expression in subclones.76 The authors also reported an independent β2M mutation leading to dysfunction in the MHC class I complex.